A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NCT07659782 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: VS-7375

Sponsor

Verastem, Inc.